Phase 2 study of inhaled SNG001 in mechanically ventilated patients with respiratory virus infection

The purpose of this Phase 2 study is to confirm safety of the dose of SNG001 to be administered to mechanically ventilated patients and to investigate whether SNG001 can boost antiviral defences at the site of infection in critically ill patients with a confirmed respiratory virus infection, potentially accelerating clearance of the virus and resulting in reduction in mortality rate, compared with standard of care (SOC). Safety and other efficacy endpoints will also be assessed.